scholarly journals Thyroid carcinoma associated with other primary neoplasms, a single center study

2021 ◽  
Author(s):  
Katalin Gabora ◽  
Ovidiu Bălăcescu ◽  
Adrian Trifa ◽  
Ana Maria Morariu ◽  
Bogdan Pop ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Thyroid Carcinoma ◽  
Survival Rates ◽  
Braf V600e Mutation ◽  
Braf V600e ◽  
Second Primary ◽  
Time Interval ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Primary Neoplasms

  Background and aims. Thyroid carcinoma is the most frequent endocrine malignancy. It develops following a complex interaction of environmental and genetic factors. Its incidence is on the rise mostly due to the frequent diagnosis of microcarcinomas (tumor<1 cm ). In most cases, it has very good prognosis and survival rates. The incidence of a second primary malignancy in thyroid cancer patients is higher than in the general population. In this article, we focus on the role of BRAF V600E mutation in the development of other primary neoplasms associated with thyroid carcinoma. Methods. This study was conducted in the department of Nuclear Medicine and Genetics of the "Prof. Dr. Ion Chiricuță” Institute of Oncology of Cluj-Napoca. We evaluated patients with thyroid carcinoma, who were diagnosed and treated for other malignancies such as breast, colorectal, lung cancer and malignant melanoma. In addition, we tested for the BRAF V600E mutation using paraffin samples of patients. Results. We identified 17 patients that had thyroid carcinoma associated with other primary malignancies. Two of the patients included in the study had three associated primary cancers. The time interval between the diagnoses of two primary neoplasms in  the same patient was 6.15 years, with a standard deviation (SD) of 5.39 years. The most common primary tumor associated with thyroid carcinoma in this study was breast cancer. We applied genetic testing for the BRAF V600E mutation in 12 patients. The BRAF V600E mutation positivity rate was 26.9% and most of the cancer associations were metachronous (occurring at least 6 months after thyroid cancer). Conclusions. The BRAF V600E mutation is an important prognostic factor in the neoplasms included in this study, but its presence is not a predictive factor for the appearance of a metachronous or synchronous associated primary neoplasm to thyroid cancer.  

Occurrence of second primary malignancy in medullary thyroid cancer (MTC) patients

2019 ◽  
Author(s):  
George Simeakis ◽  
Katerina Saltiki ◽  
Evangelia Zapanti ◽  
Evanthia Kassis ◽  
Maria Alevizaki
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Medullary Thyroid

scholarly journals Second Primary Malignancy Risk After Radioactive Iodine Treatment for Thyroid Cancer: A Systematic Review and Meta-analysis

Thyroid ◽  
2009 ◽  
Vol 19 (5) ◽  
pp. 451-457 ◽  
Author(s):  
Anna M. Sawka ◽  
Lehana Thabane ◽  
Luciana Parlea ◽  
Irada Ibrahim-Zada ◽  
Richard W. Tsang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Thyroid Cancer ◽  
Radioactive Iodine ◽  
Meta Analysis ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Malignancy Risk ◽  
Iodine Treatment

The risk of second primary cancers in clear cell and papillary renal cancer.

2015 ◽  
Vol 33 (7_suppl) ◽  
pp. 446-446 ◽  
Author(s):  
Muhammad Saad Hamid ◽  
Raji Shameem ◽  
Rishi Jain ◽  
Kevin M. Sullivan
Keyword(s):  
Thyroid Cancer ◽  
Solid Tumors ◽  
Clear Cell ◽  
Latency Period ◽  
Initial Diagnosis ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Second Primary Cancers ◽  
Increased Risk

446 Background: Renal cell carcinoma (RCC) survivors have an increased risk of developing second primary cancers. We sought to determine the role of RCC tumor histology for the risk of developing second primary solid tumors. Methods: The Surveillance Epidemiology and End Results (SEER) database was used to detect RCC cases diagnosed up to 12/31/2011. The Standardized Incidence Ratio (SIR) was calculated as the ratio of observed to expected cases of second primary malignancy based on incidence data in the general United States population. The two most common RCC histological subtypes were included; clear cell and papillary. The latency exclusion period from the date of diagnosis was 60 months. We investigated for the effect of latency period after initial diagnosis (5-10 years and >10 years) that may increase the risk for a second primary cancer. Results: A total of 2,669 patients with an initial diagnosis of RCC (clear cell: 2,368, papillary: 301) that developed second primary cancers were included in our analysis. There was a significantly increased risk of thyroid cancer (SIR: 2.30, p<0.05), prostate cancer (SIR: 1.12, p<0.05) and “all solid tumors” (SIR: 1.14, p<0.05) in clear cell RCC cases. Regarding latency period, thyroid cancer (SIR: 2.87, p<0.05) risk was increased in the 5-10 years latency period, but not in the >10 years latency period. Overall, in patients diagnosed with papillary RCC, tumors of the prostate (SIR: 1.30, p<0.05), lung (SIR: 1.78, p<0.05) and pancreas (SIR: 2.70, p<0.05) were increased. Exclusively in the 5-10 years latency period, the risk for developing lung cancer (SIR: 1.90, p<0.05) was significant. Conclusions: RCC histology may impact the risk for developing specific second primary solid tumors.

Phenotypes and prognostic factors in adults with Langerhans cell histiocytosis.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 7049-7049
Author(s):  
Gaurav Goyal ◽  
Aldo A. Acosta-Medina ◽  
Marie Hu ◽  
Jithma P. Abeykoon ◽  
Aishwarya Ravindran ◽  
...  
Keyword(s):  
Multivariate Analysis ◽  
Prognostic Factors ◽  
Langerhans Cell Histiocytosis ◽  
Univariate Analysis ◽  
Langerhans Cell ◽  
Braf V600e ◽  
Second Primary ◽  
Single Center ◽  
Second Primary Malignancy ◽  
Primary Malignancy

7049 Background: Langerhans cell histiocytosis (LCH) can manifest as single system (SS) disease, multisystem (MS) disease, or pulmonary LCH (smoking-related). There is a paucity of data on prognostic factors including risk organ (RO) involvement (liver, spleen, and bone marrow) in adult LCH, which we sought to address in this study. Methods: Single-center retrospective study of patients ≥18y diagnosed with LCH from 1998 to 2020. Univariate and multivariate analyses for progression free survival (PFS) and overall survival (OS) were conducted using age, sex, organ involvement, LCH subtype, year of diagnosis, BRAF V600E status, and treatments. Results: We included 219 patients with LCH; median age 43y (range 19-88), females 51%, SS unifocal (23%), SS multifocal (6%), pulmonary (31%) and MS (40%). Commonly involved organs included lung (53%), bone (42%), skin (24%), pituitary (16%), and CNS (12%). BRAF V600E was positive in 40/88 (46%). Median follow-up duration was 6.1y (95% CI, 5.1- 7.1). On univariate analysis, factors associated with worse PFS were bone LCH, RO involvement, multifocal/MS LCH, and radiation therapy alone; those with worse OS included RO involvement, MS disease, BRAF V600E+, and age ≥45y at diagnosis. In multivariate analysis, BRAF V600E and age ≥45y at diagnosis were associated with worse mortality (Table). Median PFS was not reached (NR-NR) for SS unifocal LCH, 5mo (0-12.7) for SS multifocal LCH, 110mo (84.7-135.3) for pulmonary LCH, and 27mo (17.2-36.8) for MS LCH. 5-year OS was 97.4% for SS unifocal LCH, 100% for SS multifocal LCH, 96.1% for pulmonary LCH, and 79.9% for MS LCH. 41 (18.7%) developed a second primary malignancy (SPM), of which 11 were hematologic neoplasms. There was a trend towards a higher prevalence of SPMs in patients with BRAF V600E (28% vs. 17%; p = 0.22). Conclusions: In our large single-center study, PFS for multifocal and MS LCH was worse than SS unifocal or pulmonary LCH. RO involvement was not associated with outcomes in multivariate analysis. Overall prognosis was excellent for all subtypes except MS LCH. BRAF V600E and older age were associated with worse OS. The prevalence of SPMs was very high and needs to be explored further.[Table: see text]

The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative131I dose over 37 GBq

2014 ◽  
Vol 83 (1) ◽  
pp. 117-123 ◽  
Author(s):  
Ah Reum Khang ◽  
Sun Wook Cho ◽  
Hoon Sung Choi ◽  
Hwa Young Ahn ◽  
Won Sang Yoo ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Cancer Patients ◽  
Differentiated Thyroid Cancer ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy

scholarly journals Incidence of Second Malignancy in Patients with Papillary Thyroid Cancer from Surveillance, Epidemiology, and End Results 13 Dataset

2018 ◽  
Vol 2018 ◽  
pp. 1-11 ◽  
Author(s):  
Mayumi Endo ◽  
Jessica B. Liu ◽  
Marcelle Dougan ◽  
Jennifer S. Lee
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Incidence Rates ◽  
Lymphocytic Leukemia ◽  
Second Primary ◽  
Papillary Thyroid ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Increased Risk ◽  
End Results

Increased risk of second primary malignancy (SPM) in papillary thyroid cancer (PTC) has been reported. Here, we present the most updated incidence rates of second primary malignancy from original diagnosis of PTC by using the data from the Surveillance, Epidemiology, and End Results. In this cohort, 3,200 patients developed SPM, a substantially higher number than in the reference population of 2,749 with observed to expected ratio (O/E) of 1.16 (95% CI; 1.12–1.21). Bone and joint cancer had the highest O/E ratio of 4.26 (95% confidence interval [CI] 2.33–7.15) followed by salivary gland (O/E 4.15; 95% CI 2.76–6.0) and acute lymphocytic leukemia (O/E 3.98; 95% CI 2.12–6.8). Mean age at the diagnosis of SPM was 64.4 years old. Interestingly, incidence of colorectal cancer was lower in thyroid cancer survivors compared to general population (large intestine O/E 0.3; 95% CI 0.06–0.88, rectum O/E 0.6; 95% CI 0.41–0.85); however, this was not observed in patients who underwent radiation therapy. The incidence of SPM at all sites was higher during 2000–2012 compared to 1992–1999 (O/E 1.24 versus 1.10). Surprisingly, patients with micropapillary cancer had higher incidence of SPM than counterparts with a larger tumor in radiation group (O/E of 1.40 versus 1.15). O/E of all cancers were higher in males compared to females with O/E of 1.41 versus 1.17 during the period of 2000–2012. Diagnosis of PTC before age 50, especially at age 30–34, was associated with higher incidence of overall SPM (age 30–34; O/E 1.43; 95% CI; 1.19–1.71). Efficient monitoring strategies that include age at the time of thyroid cancer diagnosis, exposure to radiation, gender, and genetic susceptibility may successfully detect SPM earlier in the disease course. This is especially important given the excellent prognosis of the initial thyroid cancer itself.

Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy

Surgery ◽  
2012 ◽  
Vol 151 (6) ◽  
pp. 844-850 ◽  
Author(s):  
Brian Hung-Hin Lang ◽  
Irene Oi Ling Wong ◽  
Kai Pun Wong ◽  
Benjamin J. Cowling ◽  
Koon-Yat Wan
Keyword(s):  
Thyroid Carcinoma ◽  
Radioactive Iodine ◽  
Differentiated Thyroid Carcinoma ◽  
Second Primary ◽  
Radioactive Iodine Therapy ◽  
Second Primary Malignancy ◽  
Primary Malignancy
Sign in / Sign up

Export Citation Format

Share Document